LKT Labs 是一家專(zhuān)注于防癌抗癌特殊化學(xué)品研究和開(kāi)發(fā)的公司。主要提供：癌癥藥物、藥物發(fā)現(xiàn)試劑盒、天然產(chǎn)物、廣泛的生命科學(xué)研究試劑、定制合成。
美國(guó)LKT Labs 是1988年在美國(guó)成立的，為全球提供先端的藥物研發(fā)試劑、試劑盒、委托合成，并為藥物生產(chǎn)企業(yè)提供原料，最近幾年在農(nóng)藥、水產(chǎn)養(yǎng)殖業(yè)有很大程度的開(kāi)發(fā)。在LKT Labs 可以找到在其他地方找不到的產(chǎn)品。

LKT Labs A8812 AWD 131-138 191 GABA-A

LKT Labs A8812 AWD 131-138 191 GABA-A

LKT 一級(jí)代理

LKT 一級(jí)代理

LKT P0276 Peptide 401 0.5 mg 300.1 Antimicrobial peptide found in bee and wasp venom. Mast Cell Degranulating Peptide 32908-73-9 ≥95% 2583.28 C110H188N40O24S4 CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N Ambient -20°C "Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4. PMID: 2328399.

Ennis M, Atkinson G, Pearce FL. Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds. Agents Actions. 1980 Jun;10(3):222-8. PMID: 6157320.

Hanson JM, Morley J, Soria-Herrera C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. PMID: 4152780.

"

LKT P0276 Peptide 401 1 mg 510 Antimicrobial peptide found in bee and wasp venom. Mast Cell Degranulating Peptide 32908-73-9 ≥95% 2583.28 C110H188N40O24S4 CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N Ambient -20°C "Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4. PMID: 2328399.

Ennis M, Atkinson G, Pearce FL. Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds. Agents Actions. 1980 Jun;10(3):222-8. PMID: 6157320.

Hanson JM, Morley J, Soria-Herrera C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. PMID: 4152780.

"

LKT P0276 Peptide 401 2.5 mg 900.1 Antimicrobial peptide found in bee and wasp venom. Mast Cell Degranulating Peptide 32908-73-9 ≥95% 2583.28 C110H188N40O24S4 CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N Ambient -20°C "Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4. PMID: 2328399.

Ennis M, Atkinson G, Pearce FL. Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds. Agents Actions. 1980 Jun;10(3):222-8. PMID: 6157320.

Hanson JM, Morley J, Soria-Herrera C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. PMID: 4152780.

"

LKT B6918 Brevetoxin 3 5 mg 8792.6 Polyether neurotoxin found in Karenia brevis; Nav1.4/1.5 Na+ channel activator. PbTx-3 85079-48-7 ≥95% 897.2 C50H72O14 CC1CC2C(CC3(C(O2)CC4C(O3)C(=CC(=O)O4)C)C)OC5C1OC6CC7C(CC8C(O7)(CC=CC9C(O8)CC1C(O9)CC2C(O1)(C(CC(O2)CC(=C)CO)O)C)C)(OC6(CC5)C)C Ambient -20°C Soluble in acetone, ethyl acetate, ethanol, and methanol. "Zaias J, Fleming LE, Baden DG, et al. Repeated exposure to aerosolized brevetoxin-3 induces prolonged airway hyperresponsiveness and lung inflammation in sheep. Inhal Toxicol. 2011 Mar;23(4):205-11. PMID: 21456953.

Liberona JL, Cárdenas JC, Reyes R, et al. Sodium-dependent action potentials induced by brevetoxin-3 trigger both IP3 increase and intracellular Ca2+ release in rat skeletal myotubes. Cell Calcium. 2008 Sep;44(3):289-97. PMID: 18276006.

Cao Z, George J, Baden DG, et al. Brevetoxin-induced phosphorylation of Pyk2 and Src in murine neocortical neurons involves distinct signaling pathways. Brain Res. 2007 Dec 12;1184:17-27. PMID: 17963734.

Radwan FF, Ramsdell JS. Characterization of in vitro oxidative and conjugative metabolic pathways for brevetoxin (PbTx-2). Toxicol Sci. 2006 Jan;89(1):57-65. PMID: 16221966.

Colman JR, Ramsdell JS. The type B brevetoxin (PbTx-3) adversely affects development, cardiovascular function, and survival in Medaka (Oryzias latipes) embryos. Environ Health Perspect. 2003 Dec;111(16):1920-5. PMID: 14644667.

Bottein Dechraoui MY, Ramsdell JS. Type B brevetoxins show tissue selectivity for voltage-gated sodium channels: comparison of brain, skeletal muscle and cardiac sodium channels. Toxicon. 2003 Jun;41(7):919-27. PMID: 12782093.

Berman FW, Murray TF. Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons. J Pharmacol Exp Ther. 1999 Jul;290(1):439-44. PMID: 10381810.

Jeglitsch G, Rein K, Baden DG, et al. Brevetoxin-3 (PbTx-3) and its derivatives modulate single tetrodotoxin-sensitive sodium channels in rat sensory neurons. J Pharmacol Exp Ther. 1998 Feb;284(2):516-25. PMID: 9454792.

" "UN number: 3462     Class: 6.1     Packing Group: II

Proper shipping name: Toxins, extracted from living sources, solid, n.o.s. (Brevetoxin 3)"

LKT M5853 Moniliformin 5 mg 1395.3 Mycotoxin produced by species of Fusarium; potential pyruvate dehydrogenase inhibitor. 3-hydroxycyclobut-3-ene-1,2-dione 31876-38-7 ≥98% 98.06 C4H2O3 C1=C(C(=O)C1=O)O Ambient 4°C water, methanol "Scarpino V, Blandino M, Negre M, et al. Moniliformin analysis in maize samples from North-West Italy using multifunctional clean-up columns and the LC-MS/MS detection method. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(5):876-84. PMID: 23731218.

Ficheux AS, Sibiril Y, Parent-Massin D. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: an in vitro study. Toxicon. 2013 Sep;71:1-10. PMID: 23685117.

von Bargen KW, Lohrey L, Cramer B, et al. Analysis of the Fusarium mycotoxin moniliformin in cereal samples using 13C2-moniliformin and high-resolution mass spectrometry. J Agric Food Chem. 2012 Apr 11;60(14):3586-91. PMID: 22428531.

Zhang A, Cao JL, Yang B, et al. Effects of moniliformin and selenium on human articular cartilage metabolism and their potential relationships to the pathogenesis of Kashin-Beck disease. J Zhejiang Univ Sci B. 2010 Mar;11(3):200-8. PMID: 20205306.

Chen LY, Tian XL, Yang B. A study on the inhibition of rat myocardium glutathione peroxidase and glutathione reductase by moniliformin. Mycopathologia. 1990 May;110(2):119-24. PMID: 2366852.

Gathercole PS, Thiel PG, Hofmeyr JH. Inhibition of pyruvate dehydrogenase complex by moniliformin. Biochem J. 1986 Feb 1;233(3):719-23. PMID: 3707519.

" "UN number: 3462     Class: 6.1     Packing Group: II

Proper shipping name: Toxins, extracted from living sources, solid, n.o.s. (Moniliformin)"

LKT K0021 K252a 5 mg 842.6 Staurosporine analog; PKC inhibitor, TrkA/B antagonist. SF 2370 99533-80-9 ≥98% 467.48 C27H21N3O5 CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O Ambient 4°C "Readily soluble in chloroform, acetonitrile, acetone, dioxane, tetrahydrofuran, pyridine;

soluble in ethanol, methanol, 1-propanol, ethyl acetate and n-butanol;

insoluble in water, 2-propanol" "El-Hashim AZ, Jaffal SM, Al-Rashidi FT, et al. Nerve growth factor enhances cough via a central mechanism of action. Pharmacol Res. 2013 Aug;74:68-77. PMID: 23742790.

Cardenas-Aguayo Mdel C, Kazim SF, Grundke-Iqbal I, et al. Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures. PLoS One. 2013;8(1):e53596. PMID: 23320097.

Sugiya H, Putney JW Jr. Protein kinase C-dependent and -independent mechanisms regulating the parotid substance P receptor as revealed by differential effects of protein kinase C inhibitors. Biochem J. 1988 Dec 1;256(2):677-80. PMID: 2464997.

Hashimoto S. K-252a, a potent protein kinase inhibitor, blocks nerve growth factor-induced neurite outgrowth and changes in the phosphorylation of proteins in PC12h cells. J Cell Biol. 1988 Oct;107(4):1531-9. PMID: 2844830.

" Xi Not dangerous goods.

LKT A6925 L-Arginine Ethyl Ester Dihydrochloride 5 g 39.4 Arginine source used to increase NO production. 36589-29-4 ≥98% 275.18 C8H18N4O2 Ambient -20°C "Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the ""L-arginine paradox"". Biochem Biophys Res Commun. 2011 Nov 4;414(4):660-3. PMID: 21986532.

Knecht KR, Milam S, Wilkinson DA, et al. Time-dependent action of carbon monoxide on the newborn cerebrovascular circulation. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H70-5. PMID: 20435844.

" Not dangerous goods.

LKT A6925 L-Arginine Ethyl Ester Dihydrochloride 25 g 140.5 Arginine source used to increase NO production. 36589-29-4 ≥98% 275.18 C8H18N4O2 Ambient -20°C "Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the ""L-arginine paradox"". Biochem Biophys Res Commun. 2011 Nov 4;414(4):660-3. PMID: 21986532.

Knecht KR, Milam S, Wilkinson DA, et al. Time-dependent action of carbon monoxide on the newborn cerebrovascular circulation. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H70-5. PMID: 20435844.

" Not dangerous goods.

LKT A0001 A-803467 10 mg 84.3 Nav1.8 Na+ channel blocker, potential Nav1.5 Na+ channel blocker. 944261-79-4 357.79 C19H16ClNO4 "COc1cc(cc(c1)OC)NC(=O)c2ccc(o2)c3ccc(cc3)Cl

" Ambient -20°C "Rahman W, Dickenson AH. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. Neuroscience. 2015 Jun 4;295:103-16. PMID: 25818052.

Han Z, Jiang Y, Xiao F, et al. The effects of A-803467 on cardiac Nav1.5 channels. Eur J Pharmacol. 2015 May 5;754:52-60. PMID: 25701724.

Liu XD, Yang JJ, Fang D, et al. Functional upregulation of Nav1.8 sodium channels on the membrane of dorsal root Ganglia neurons contributes to the development of cancer-induced bone pain. PLoS One. 2014 Dec 11;9(12):e114623. PMID: 25503076.

Qi B, Wei Y, Chen S, et al. Nav1.8 channels in ganglionated plexi modulate atrial fibrillation inducibility. Cardiovasc Res. 2014 Jun 1;102(3):480-6. PMID: 24419303.

" Not dangerous goods.

LKT A0001 A-803467 50 mg 292.1 Nav1.8 Na+ channel blocker, potential Nav1.5 Na+ channel blocker. 944261-79-4 357.79 C19H16ClNO4 "COc1cc(cc(c1)OC)NC(=O)c2ccc(o2)c3ccc(cc3)Cl

" Ambient -20°C "Rahman W, Dickenson AH. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. Neuroscience. 2015 Jun 4;295:103-16. PMID: 25818052.

Han Z, Jiang Y, Xiao F, et al. The effects of A-803467 on cardiac Nav1.5 channels. Eur J Pharmacol. 2015 May 5;754:52-60. PMID: 25701724.

Liu XD, Yang JJ, Fang D, et al. Functional upregulation of Nav1.8 sodium channels on the membrane of dorsal root Ganglia neurons contributes to the development of cancer-induced bone pain. PLoS One. 2014 Dec 11;9(12):e114623. PMID: 25503076.

Qi B, Wei Y, Chen S, et al. Nav1.8 channels in ganglionated plexi modulate atrial fibrillation inducibility. Cardiovasc Res. 2014 Jun 1;102(3):480-6. PMID: 24419303.

" Not dangerous goods.

LKT B5044 BML-277 5 mg 84.3 Arylbenzimidazole; CHK2 inhibitor. 516480-79-8 ≥98% 363.8 C20H14ClN3O2 Ambient Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. PMID: 15771432. Not dangerous goods.

LKT B5044 BML-277 25 mg 337.1 Arylbenzimidazole; CHK2 inhibitor. 516480-79-8 ≥98% 363.8 C20H14ClN3O2 Ambient Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. PMID: 15771432. Not dangerous goods.

LKT B8676 BVT-2733 5 mg 78.6 11β-HSD1 inhibitor. BVT2733 376640-41-4 428.96 C17H21ClN4O3S2 "Cc1c(cccc1Cl)S(=O)(=O)Nc2nc(cs2)CC(=O)N3CCN(CC3)C

" Ambient "Zhang L, Dong Y, Zou F, et al. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17(3):489-94. PMID: 23938253.

Wu L, Qi H, Zhong Y, et al. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. Endocr J. 2013;60(9):1047-58. PMID: 23759754.

Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002 Nov;45(11):1528-32. PMID: 12436336.

" Not dangerous goods.

LKT B8676 BVT-2733 25 mg 320.3 11β-HSD1 inhibitor. BVT2733 376640-41-4 428.96 C17H21ClN4O3S2 "Cc1c(cccc1Cl)S(=O)(=O)Nc2nc(cs2)CC(=O)N3CCN(CC3)C

" Ambient "Zhang L, Dong Y, Zou F, et al. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17(3):489-94. PMID: 23938253.

Wu L, Qi H, Zhong Y, et al. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. Endocr J. 2013;60(9):1047-58. PMID: 23759754.

Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002 Nov;45(11):1528-32. PMID: 12436336.

" Not dangerous goods.

LKT P2100 PF-06447475 5 mg 73.1 LRRK2 inhibitor. 1527473-33-1 305.13 C17H15N5O Ambient "Daher JP, Abdelmotilib HA, Hu X, et al. LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration. J Biol Chem. 2015 Jun 15. [Epub ahead of print]. PMID: 26078453.

Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. PMID: 25353650.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (PF06447475)"

LKT P2100 PF-06447475 25 mg 280.9 LRRK2 inhibitor. 1527473-33-1 305.13 C17H15N5O Ambient "Daher JP, Abdelmotilib HA, Hu X, et al. LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration. J Biol Chem. 2015 Jun 15. [Epub ahead of print]. PMID: 26078453.

Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. PMID: 25353650.

" "UN number: 2811     Class: 6.1     Packing Group: III

Proper shipping name: Toxic solid, organic, n.o.s. (PF06447475)"

LKT A1592 ADX-47273 5 mg 235.9 mGluR5 positive modulator. 851881-60-2 369.36 C20H17F2N3O2 "c1cc(ccc1c2nc(on2)C3CCCN(C3)C(=O)c4ccc(cc4)F)F

" Ambient "Ahnaou A, Langlois X, Steckler T, et al. Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats. Psychopharmacology (Berl). 2015 Mar;232(6):1107-22. PMID: 25323624.

Xu J, Zhu Y, Kraniotis S, et al. Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning. Learn Mem. 2013 Jul 18;20(8):438-45. PMID: 23869026.

Kroker KS, Rast G, Rosenbrock H. Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology. 2011 Sep;61(4):707-14. PMID: 21640734.

Schlumberger C, Pietraszek M, Gravius A, et al. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83. PMID: 19765575.

Liu F, Grauer S, Kelley C, et al. ADX47273 [S-(4-fluoro-phenyl)--methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. PMID: 18753411.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (ADX47273)"

LKT A1592 ADX-47273 25 mg 814.6 mGluR5 positive modulator. 851881-60-2 369.36 C20H17F2N3O2 "c1cc(ccc1c2nc(on2)C3CCCN(C3)C(=O)c4ccc(cc4)F)F

" Ambient "Ahnaou A, Langlois X, Steckler T, et al. Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats. Psychopharmacology (Berl). 2015 Mar;232(6):1107-22. PMID: 25323624.

Xu J, Zhu Y, Kraniotis S, et al. Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning. Learn Mem. 2013 Jul 18;20(8):438-45. PMID: 23869026.

Kroker KS, Rast G, Rosenbrock H. Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology. 2011 Sep;61(4):707-14. PMID: 21640734.

Schlumberger C, Pietraszek M, Gravius A, et al. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83. PMID: 19765575.

Liu F, Grauer S, Kelley C, et al. ADX47273 [S-(4-fluoro-phenyl)--methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. PMID: 18753411.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (ADX47273)"

LKT S6800 SR1001 5 mg 84.3 RORα/γ inverse agonist. 1335106-03-0 ≥98% 477.4 C15H13F6N3O4S2 Ambient -20°C "Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015 Mar;156(3):869-81. PMID: 25560829.

Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013 Apr 1;73(7):622-30. PMID: 23174342.

Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4. PMID: 21499262.

" Not dangerous goods.

LKT S6800 SR1001 25 mg 365.2 RORα/γ inverse agonist. 1335106-03-0 ≥98% 477.4 C15H13F6N3O4S2 Ambient -20°C "Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015 Mar;156(3):869-81. PMID: 25560829.

Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013 Apr 1;73(7):622-30. PMID: 23174342.

Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4. PMID: 21499262.

" Not dangerous goods.

LKT S6800 SR1001 100 mg 1095.5 RORα/γ inverse agonist. 1335106-03-0 ≥98% 477.4 C15H13F6N3O4S2 Ambient -20°C "Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015 Mar;156(3):869-81. PMID: 25560829.

Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013 Apr 1;73(7):622-30. PMID: 23174342.

Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4. PMID: 21499262.

" Not dangerous goods.

LKT T3196 Thymoquinone 1 g 39.4 Phytochemical from Nigella sativa. 2-Isopropyl-5-methylbenzo-1,4-quinone 2-Isopropyl-5-methyl-1,4-benzoquinone 490-91-5 ≥98% 164.2 C10H12O2 "CC1=CC(=O)C(=CC1=O)C(C)C

" Ambient Ambient "Linjawi SA, Khalil WK, Hassanane MM, et al. Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats. Arch Med Sci. 2015 Mar 16;11(1):220-9. PMID: 25861310.

ElKhoely A, Hafez HF, Ashmawy AM, et al. Chemopreventive and therapeutic potentials of thymoquinone in HepG2 cells: mechanistic perspectives. J Nat Med. 2015 Mar 22. [Epub ahead of print]. PMID: 25796541.

Pejman L, Omrani H, Mirzamohammadi Z, et al. Thymoquinone, the main constituent of Nigella sativa, affects adenosine receptors in asthmatic guinea pigs. Iran J Basic Med Sci. 2014 Dec;17(12):1012-9. PMID: 25859306.

Mehri S, Shahi M, Razavi BM, et al. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iran J Basic Med Sci. 2014 Dec;17(12):1007-11. PMID: 25859305.

" Not dangerous goods.

LKT T3196 Thymoquinone 5 g 129.3 Phytochemical from Nigella sativa. 2-Isopropyl-5-methylbenzo-1,4-quinone 2-Isopropyl-5-methyl-1,4-benzoquinone 490-91-5 ≥98% 164.2 C10H12O2 "CC1=CC(=O)C(=CC1=O)C(C)C

" Ambient Ambient "Linjawi SA, Khalil WK, Hassanane MM, et al. Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats. Arch Med Sci. 2015 Mar 16;11(1):220-9. PMID: 25861310.

ElKhoely A, Hafez HF, Ashmawy AM, et al. Chemopreventive and therapeutic potentials of thymoquinone in HepG2 cells: mechanistic perspectives. J Nat Med. 2015 Mar 22. [Epub ahead of print]. PMID: 25796541.

Pejman L, Omrani H, Mirzamohammadi Z, et al. Thymoquinone, the main constituent of Nigella sativa, affects adenosine receptors in asthmatic guinea pigs. Iran J Basic Med Sci. 2014 Dec;17(12):1012-9. PMID: 25859306.

Mehri S, Shahi M, Razavi BM, et al. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iran J Basic Med Sci. 2014 Dec;17(12):1007-11. PMID: 25859305.

" Not dangerous goods.

LKT N6272 NPS-2143 Hydrochloride 5 mg 101.1 Ca2+-sensing receptor antagonist. 324523-20-8 ≥98% 445.38 C24H25ClN2O2 HCl Ambient -20°C "Dal Prà I, Chiarini A, Pacchiana R, et al. Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease. Curr Neuropharmacol. 2014 Jul;12(4):353-64. PMID: 25342943.

Dal Prà I, Armato U, Chioffi F, et al. The Aβ peptides-activated calcium-sensing receptor stimulates the production and secretion of vascular endothelial growth factor-A by normoxic adult human cortical astrocytes. Neuromolecular Med. 2014 Dec;16(4):645-57. PMID: 24948534.

Yamamura A. Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension. J Smooth Muscle Res. 2014;50:8-17. PMID: 24770445.

Nakajima S, Hira T, Hara H. Calcium-sensing receptor mediates dietary peptide-induced CCK secretion in enteroendocrine STC-1 cells. Mol Nutr Food Res. 2012 May;56(5):753-60. PMID: 22648622.

Nemeth EF, Delmar EG, Heaton WL, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001 Oct;299(1):323-31. PMID: 11561095.

Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000 Jun;105(11):1595-604. PMID: 10841518.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (NPS-2143 hydrochloride)"

LKT N6272 NPS-2143 Hydrochloride 25 mg 426.9 Ca2+-sensing receptor antagonist. 324523-20-8 ≥98% 445.38 C24H25ClN2O2 HCl Ambient -20°C "Dal Prà I, Chiarini A, Pacchiana R, et al. Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease. Curr Neuropharmacol. 2014 Jul;12(4):353-64. PMID: 25342943.

Dal Prà I, Armato U, Chioffi F, et al. The Aβ peptides-activated calcium-sensing receptor stimulates the production and secretion of vascular endothelial growth factor-A by normoxic adult human cortical astrocytes. Neuromolecular Med. 2014 Dec;16(4):645-57. PMID: 24948534.

Yamamura A. Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension. J Smooth Muscle Res. 2014;50:8-17. PMID: 24770445.

Nakajima S, Hira T, Hara H. Calcium-sensing receptor mediates dietary peptide-induced CCK secretion in enteroendocrine STC-1 cells. Mol Nutr Food Res. 2012 May;56(5):753-60. PMID: 22648622.

Nemeth EF, Delmar EG, Heaton WL, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther. 2001 Oct;299(1):323-31. PMID: 11561095.

Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000 Jun;105(11):1595-604. PMID: 10841518.

" "UN number: 3077     Class: 9     Packing Group: III

Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (NPS-2143 hydrochloride)"

LKT C3352 Cinacalcet Hydrochloride 5 mg 50.6 Ca2+-sensing receptor agonist. 364782-34-3 ≥98% 393.87 C22H22F3N HCl "CC(c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F.Cl

" Ambient Ambient "Kuczera P, Adamczak M, Machnik G, et al. Treatment with Cinacalcet Increases Plasma Adiponectin Concentration in Hemodialysed Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism. Endocr Pract. 2015 Mar 18:1-22. [Epub ahead of print]. PMID: 25786554.

Wu M, Tang RN, Liu H, et al. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F138-46. PMID: 24154694.

" Not dangerous goods.

LKT C3352 Cinacalcet Hydrochloride 25 mg 163 Ca2+-sensing receptor agonist. 364782-34-3 ≥98% 393.87 C22H22F3N HCl "CC(c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F.Cl

" Ambient Ambient "Kuczera P, Adamczak M, Machnik G, et al. Treatment with Cinacalcet Increases Plasma Adiponectin Concentration in Hemodialysed Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism. Endocr Pract. 2015 Mar 18:1-22. [Epub ahead of print]. PMID: 25786554.

Wu M, Tang RN, Liu H, et al. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F138-46. PMID: 24154694.

" Not dangerous goods.

LKT C3352 Cinacalcet Hydrochloride 100 mg 505.6 Ca2+-sensing receptor agonist. 364782-34-3 ≥98% 393.87 C22H22F3N HCl "CC(c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F.Cl

" Ambient Ambient "Kuczera P, Adamczak M, Machnik G, et al. Treatment with Cinacalcet Increases Plasma Adiponectin Concentration in Hemodialysed Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism. Endocr Pract. 2015 Mar 18:1-22. [Epub ahead of print]. PMID: 25786554.

Wu M, Tang RN, Liu H, et al. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F138-46. PMID: 24154694.

" Not dangerous goods.

LKT F4432 FLI-06 5 mg 84.3 Dihydropyridine; γ-secretase inhibitor. 1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester 313967-18-9 ≥98% 438.52 C25H30N2O5 Ambient -20°C Kr?mer A, Mentrup T, Kleizen B, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol. 2013 Nov;9(11):731-8. PMID: 24077179. Not dangerous goods.

LKT F4432 FLI-06 25 mg 359.5 Dihydropyridine; γ-secretase inhibitor. 1,4,5,6,7,8-Hexahydro-2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-3-quinolinecarboxylic acid cyclohexyl ester 313967-18-9 ≥98% 438.52 C25H30N2O5 Ambient -20°C Kr?mer A, Mentrup T, Kleizen B, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol. 2013 Nov;9(11):731-8. PMID: 24077179. Not dangerous goods.

LKT L9701 LY-450139 5 mg 185.4 GHS-R1a agonist, γ-secretase inhibitor. Semagacestat 425386-60-3 ≥98% 361.44 C19H27N3O4 Ambient -20°C "Beggiato S, Giuliani A, Sivilia S, et al. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. PMID: 24530449.

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. PMID: 23883379.

Schellekens H, McNamara O, Dinan TG, et al. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. PMID: 23488781.

" Not dangerous goods.

LKT L9701 LY-450139 25 mg 634.8 GHS-R1a agonist, γ-secretase inhibitor. Semagacestat 425386-60-3 ≥98% 361.44 C19H27N3O4 Ambient -20°C "Beggiato S, Giuliani A, Sivilia S, et al. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. PMID: 24530449.

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. PMID: 23883379.

Schellekens H, McNamara O, Dinan TG, et al. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. PMID: 23488781.

" Not dangerous goods.

LKT L9701 LY-450139 50 mg 1067.3 GHS-R1a agonist, γ-secretase inhibitor. Semagacestat 425386-60-3 ≥98% 361.44 C19H27N3O4 Ambient -20°C "Beggiato S, Giuliani A, Sivilia S, et al. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. PMID: 24530449.

Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. PMID: 23883379.

Schellekens H, McNamara O, Dinan TG, et al. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. PMID: 23488781.

" Not dangerous goods.

LKT M4200 MK-0752 1 mg 56.2 γ-Secretase inhibitor. 471905-41-6 ≥98% 442.9 C21H21ClF2O4S "c1cc(ccc1S(=O)(=O)C2(CCC(CC2)CCC(=O)O)c3cc(ccc3F)F)Cl

" Ambient -20°C "Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.

Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.

" Not dangerous goods.

LKT M4200 MK-0752 5 mg 269.6 γ-Secretase inhibitor. 471905-41-6 ≥98% 442.9 C21H21ClF2O4S "c1cc(ccc1S(=O)(=O)C2(CCC(CC2)CCC(=O)O)c3cc(ccc3F)F)Cl

" Ambient -20°C "Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.

Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.

" Not dangerous goods.

LKT M4200 MK-0752 25 mg 837.1 γ-Secretase inhibitor. 471905-41-6 ≥98% 442.9 C21H21ClF2O4S "c1cc(ccc1S(=O)(=O)C2(CCC(CC2)CCC(=O)O)c3cc(ccc3F)F)Cl

" Ambient -20°C "Hoffman LM, Fouladi M, Olson J, et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. PMID: 25930724.

Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33. PMID: 18220929.

" Not dangerous goods.

LKT D1773 Deshydroxy LY-411575 5 mg 89.9 γ-Secretase inhibitor. YO-01027, Dibenzazepine 209984-56-5 ≥98% 463.48 C26H23F2N3O3 Ambient -20°C "Petersen N, Reimann F, van Es JH, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest. 2015 Jan;125(1):379-85. PMID: 25500886.

Xiao Z, Zhang J, Peng X, et al. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation. Int J Biochem Cell Biol. 2014 Oct;55:65-71. PMID: 25150830.

Zheng YH, Li FD, Tian C, et al. Notch γ-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One. 2013 Dec 16;8(12):e83310. PMID: 24358274.

" Not dangerous goods.

LKT D1773 Deshydroxy LY-411575 25 mg 365.2 γ-Secretase inhibitor. YO-01027, Dibenzazepine 209984-56-5 ≥98% 463.48 C26H23F2N3O3 Ambient -20°C "Petersen N, Reimann F, van Es JH, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest. 2015 Jan;125(1):379-85. PMID: 25500886.

Xiao Z, Zhang J, Peng X, et al. The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation. Int J Biochem Cell Biol. 2014 Oct;55:65-71. PMID: 25150830.

Zheng YH, Li FD, Tian C, et al. Notch γ-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One. 2013 Dec 16;8(12):e83310. PMID: 24358274.

" Not dangerous goods.

LKT D0260 DAPT 5 mg 78.6 γ-Secretase inhibitor. GSI-IX 208255-80-5 ≥98% 432.47 C23H26F2N2O4 Ambient -20°C Liu J, Mao Z, Huang J, et al. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. PMID: 24502949. Not dangerous goods.

LKT D0260 DAPT 25 mg 280.9 γ-Secretase inhibitor. GSI-IX 208255-80-5 ≥98% 432.47 C23H26F2N2O4 Ambient -20°C Liu J, Mao Z, Huang J, et al. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. PMID: 24502949. Not dangerous goods.

LKT P4782 PluriSln 1 5 mg 61.8 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT P4782 PluriSln 1 10 mg 103.3 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT P4782 PluriSln 1 25 mg 213.5 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT P4782 PluriSln 1 50 mg 331.5 Stearoyl-coA desaturase 1 inhibitor. NSC 14613 91396-88-2 ≥98% 213.24 C12H11N3O Ambient "Zhang L, Pan Y, Qin G, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. PMID: 24394703.

Ben-David U, Gan QF, Golan-Lev T, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. PMID: 23318055.

" Not dangerous goods.

LKT N3350 Nimorazole 5 mg 118 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT N3350 Nimorazole 10 mg 196.7 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT N3350 Nimorazole 25 mg 393.2 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT N3350 Nimorazole 50 mg 561.8 Nitroimidazole; hypoxic modifier and radiosensitizer. 6506-37-2 ≥98% 226.24 C9H14N4O3 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] Ambient "

Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.

Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.

Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.

Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.

" Not dangerous goods.

LKT A8812 AWD 131-138 5 mg 101.1 GABA-A positive modulator. 188116-07-6 ≥98% 279.72 C13H14ClN3O2 c1cc(ccc1N2CC(=NC2=O)N3CCOCC3)Cl Ambient "Rundfeldt C, L?scher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014 Jan;28(1):29-43. PMID: 24357084.

L?scher W, Hoffmann K, Twele F, et al. The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacol Res. 2013 Nov;77:39-46. PMID: 24056205.

Yasar S, Bergman J, Munzar P, et al. Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. Eur J Pharmacol. 2003 Apr 4;465(3):257-65. PMID: 12681437.

" Not dangerous goods.

LKT A8812 AWD 131-138 10 mg 191 GABA-A positive modulator. 188116-07-6 ≥98% 279.72 C13H14ClN3O2 c1cc(ccc1N2CC(=NC2=O)N3CCOCC3)Cl Ambient "Rundfeldt C, L?scher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014 Jan;28(1):29-43. PMID: 24357084.

L?scher W, Hoffmann K, Twele F, et al. The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacol Res. 2013 Nov;77:39-46. PMID: 24056205.

Yasar S, Bergman J, Munzar P, et al. Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. Eur J Pharmacol. 2003 Apr 4;465(3):257-65. PMID: 12681437.

" Not dangerous goods.